Exploring targeted therapy and immunotherapy for advanced liver and biliary tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enroll approximately 2000 patients with advanced hepatobiliary tumors across 20 research centers. It will investigate the effectiveness of targeted therapies and immunotherapies in improving survival and quality of life while assessing the safety of these treatments. Patients will be monitored monthly, and data on genetic variations will be collected to analyze correlations with treatment outcomes. The study plans to conduct interim analyses as enrollment progresses over a period of five years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects must meet all of the following criteria：

1. ≥18 years old, gender is not limited, and life expectancy is at least 6 months.
2. Diagnosed as primary liver cancer or biliary malignant tumor by histopathology or confirmed by imaging as HCC (by the American Association for the Study of Liver Diseases or standard for the diagnosis and treatment of primary liver cancer 2017 in China).
3. The Barcelona staging classification: class B-C.
4. Child-Pugh classification: class A-B.
5. At least one measurable lesion (RECIST v1.1)
6. Unable to perform radical surgery or patient refuse surgery.
7. Subjects need palliative treatment, and have received or are undergoing any of the following three treatments:

   * Monotherapy or combination therapy with targeted drug associated with genetic variation in the subject.
   * Or, treat with pan-target anti-vascular drugs, such as sorafenib, regorafenib, lenvatinib, apatinib.
   * Or, immunotherapy or immunotherapy combined with targeted therapy or (and) classical chemotherapy.
8. Subjects volunteer to participate in the study and sign informed consent.

Exclusion Criteria:

Patients with one or more of the following criteria should be excluded:

1. Patients with early hepatobiliary tumor.
2. The Barcelona staging classification: class A.
3. Child-Pugh classification: class C.
4. Radical surgical resection.
5. CT or MRI shows unclear tumor boundary or no measurable lesions (RECIST v1.1).
6. Drug abuse, or any medical, psychological, or social condition that may affect the study, patient compliance, or even compromise the safety of the patient.
7. Conduct other experimental drug treatments other than this test within 4 weeks before the start of the study; or participate in another clinical study that has an impact on the results of this study.
8. Mental or medical instability makes patients unable or unwilling to sign informed consent.
9. Patients after comprehensive assessment are considered by the investigators to be unsuitable for participating in the study.

Where it's running

• Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
  Beijing, Beijing, China Recruiting

Study contacts

• Study coordinator: Xiaobo Yang
• Email: zhaoht@pumch.cn
• Phone: 010-69156043

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New target method for treating high-grade glioma patients

  This study tests a new way of targeting radiation treatment for patients with high-grade glioma to see if it helps them live longer without their cancer getting worse and reduces side effects compared to the standard method.

  Recruiting Zhujiang Hospital · Guangzhou · NCT06215495

• Long-term follow-up for patients treated with CAR T cells

  This study looks at how well CAR T cell therapy works and its long-term safety for patients up to 15 years after their treatment.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05024175

• Adebrelimab plus platinum chemotherapy before surgery for operable esophageal squamous cell carcinoma

  This trial will try giving adebrelimab with platinum-based chemotherapy before surgery in people with locally advanced, resectable esophageal squamous cell carcinoma to see if it increases complete tumor disappearance and is safe.

  Recruiting The Second Hospital of Shandong University · Jinan · NCT07430579

• Dose-adjusted EPOCH infusions for frail adults with acute lymphoblastic leukemia

  This project will see if a dose-adjusted, infusion-based EPOCH chemotherapy regimen helps frail adults with acute lymphoblastic leukemia tolerate treatment better and live longer.

  Recruiting Hospital General de Mexico · Mexico City, Mexico City · NCT07258043

• Using Metformin with FOLFIRI chemotherapy for metastatic colorectal cancer

  This study is testing if adding Metformin to FOLFIRI chemotherapy can help people with metastatic colorectal cancer live longer and feel better.

  Recruiting Phase 2 Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City · NCT06826092

• Comparing microwave ablation and liver surgery for treating intrahepatic cholangiocarcinoma

  This study is testing whether microwave ablation can be a good first treatment option for people with a specific type of liver cancer compared to traditional liver surgery.

  Recruiting Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT06462742

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.